AC Immune
ACIU
45 hedge funds and large institutions have $114M invested in AC Immune in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 6 closing their positions.
419% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $219K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $85.7M → $114M (+$28.3M)
22% more funds holding
Funds holding: 37 → 45 (+8)
0.39% less ownership
Funds ownership: 29.2% → 28.8% (-0.39%)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.09M |
| 3 |
Renaissance Technologies
New York
|
+$451K |
| 4 |
Millennium Management
New York
|
+$352K |
| 5 |
Two Sigma Investments
New York
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$12.1M |
| 2 |
Morgan Stanley
New York
|
-$4.32M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$659K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$473K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$348K |
ACIU Hedge Fund Activity: Q2 2024 in Review
45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q2 2024, worth a combined $114M — up 33% from $85.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ACIU positions and 6 closed out — a net gain of 8 holders — while 8 added to existing stakes and 16 trimmed.
The largest buyer was BVF Inc, adding an estimated $14.1M. The largest seller was Avidity Partners Management, cutting an estimated $12.1M.
- 45 institutional investors held AC Immune (ACIU) as of Q2 2024, up from 37 in Q1 2024.
- Funds reported $114M of AC Immune stock for Q2 2024, up 33% quarter-over-quarter.
- 14 funds opened new AC Immune positions in Q2 2024 and 6 closed out, a net change of +8 holders.
- The largest AC Immune buyer in Q2 2024 was BVF Inc, an estimated $14.1M added.
- The largest AC Immune seller in Q2 2024 was Avidity Partners Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2024.